| __timestamp | Neurocrine Biosciences, Inc. | Sarepta Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 17986000 | 49315000 |
| Thursday, January 1, 2015 | 32480000 | 75043000 |
| Friday, January 1, 2016 | 68081000 | 83749000 |
| Sunday, January 1, 2017 | 169906000 | 122682000 |
| Monday, January 1, 2018 | 248932000 | 207761000 |
| Tuesday, January 1, 2019 | 354100000 | 284812000 |
| Wednesday, January 1, 2020 | 433300000 | 317875000 |
| Friday, January 1, 2021 | 583300000 | 282660000 |
| Saturday, January 1, 2022 | 752700000 | 451421000 |
| Sunday, January 1, 2023 | 887600000 | 481871000 |
| Monday, January 1, 2024 | 1007200000 |
Igniting the spark of knowledge
In the competitive landscape of biotechnology, understanding financial trends is crucial. Over the past decade, Neurocrine Biosciences, Inc. and Sarepta Therapeutics, Inc. have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Neurocrine's SG&A expenses surged by nearly 4,800%, reflecting its aggressive expansion and strategic investments. In contrast, Sarepta's expenses grew by approximately 878%, indicating a more measured approach.
By 2023, Neurocrine's SG&A expenses were nearly double those of Sarepta, highlighting its commitment to scaling operations. This trend underscores the differing strategies of these biotech giants: while Neurocrine focuses on rapid growth, Sarepta maintains a steady pace. These insights provide a window into the operational priorities and market positioning of these companies, offering valuable lessons for investors and industry analysts alike.
Pfizer Inc. and Sarepta Therapeutics, Inc.: SG&A Spending Patterns Compared
Vertex Pharmaceuticals Incorporated vs Sarepta Therapeutics, Inc.: SG&A Expense Trends
Genmab A/S or Sarepta Therapeutics, Inc.: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing Neurocrine Biosciences, Inc. and BioMarin Pharmaceutical Inc.
Operational Costs Compared: SG&A Analysis of Neurocrine Biosciences, Inc. and Jazz Pharmaceuticals plc
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Viking Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Merus N.V.
SG&A Efficiency Analysis: Comparing Neurocrine Biosciences, Inc. and BioCryst Pharmaceuticals, Inc.
Sarepta Therapeutics, Inc. or Halozyme Therapeutics, Inc.: Who Manages SG&A Costs Better?
Breaking Down SG&A Expenses: Sarepta Therapeutics, Inc. vs Ultragenyx Pharmaceutical Inc.
Sarepta Therapeutics, Inc. vs Catalyst Pharmaceuticals, Inc.: SG&A Expense Trends
Sarepta Therapeutics, Inc. vs Veracyte, Inc.: SG&A Expense Trends